Literature DB >> 9610134

Rhinocerebral zygomycosis.

K Parthiban1, S Gnanaguruvelan, C Janaki, G Sentamilselvi, J M Boopalraj.   

Abstract

An unusual case of rhinocerebral zygomycosis with its clinical and histopathological features are presented. A good response was observed with oral itraconazole at a dose of 200 mg day-1 for a period of 3 months. To our knowledge, it is the first case report of this infection, involving the maxillary sinus, eye and the brain, from Madras, Tamilnadu, India.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9610134     DOI: 10.1111/j.1439-0507.1998.tb00376.x

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  7 in total

1.  Rhino-orbital-cerebral mucormycosis.

Authors:  Maria N Gamaletsou; Nikolaos V Sipsas; Emmanuel Roilides; Thomas J Walsh
Journal:  Curr Infect Dis Rep       Date:  2012-08       Impact factor: 3.725

2.  Apophysomyces elegans: epidemiology, amplified fragment length polymorphism typing, and in vitro antifungal susceptibility pattern.

Authors:  A Chakrabarti; M R Shivaprakash; I Curfs-Breuker; A Baghela; C H Klaassen; J F Meis
Journal:  J Clin Microbiol       Date:  2010-09-29       Impact factor: 5.948

3.  In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes.

Authors:  Qiu N Sun; Annette W Fothergill; Dora I McCarthy; Michael G Rinaldi; John R Graybill
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

Review 4.  Current perspectives on ophthalmic mycoses.

Authors:  Philip A Thomas
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

Review 5.  Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3).

Authors:  Anna Skiada; Fanny Lanternier; Andreas H Groll; Livio Pagano; Stephan Zimmerli; Raoul Herbrecht; Olivier Lortholary; George L Petrikkos
Journal:  Haematologica       Date:  2012-09-14       Impact factor: 9.941

6.  In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model.

Authors:  Qiu N Sun; Laura K Najvar; Rosie Bocanegra; David Loebenberg; John R Graybill
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

7.  Zygomycosis in Immunocompromised non-Haematological Patients.

Authors:  George Petrikkos; Miranda Drogari-Apiranthitou
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-03-15       Impact factor: 2.576

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.